Official: COV-Iran Vaccine Developed through 100% Iranian Technical Know-How
TEHRAN (FNA)- Chairman of the Board of Directors of Barekat Pharmaceutical Group Hamidreza Jamshidi said on Wednesday that the technical know-how of the home-made COV-Iran Barekat vaccine is completely Iranian.
"The technical know-how of COV-Iran vaccine is 100% Iranian and this know-how was developed as a result of efforts of dozens of motivated and knowledgeable young people with round-the-clock efforts,” Jamshidi said days after the vaccine received the license for emergency injection.
He explained that phase one of the mass-production of COV-Iran started ten months ago with a capacity of 740 liters of bioreactor and the possibility of producing three to four million doses of vaccine per month, adding that phase two started six months ago with the capacity of 1,300 liters.
Jamshidi said that phase three that included mass-production started six months ago with a capacity of 3,000 liters of bioreactor and the monthly production capacity of eight to ten million doses of vaccine.
He also said that based on the results of three phases of injection of vaccine on volunteers in Iran, in addition to the Wuhan virus, COV-Iran vaccine is quite effective against the British virus mutation and is being also studied against Indian and African mutations.
Senior member of Iran’s National Task Force for Fighting COVID-19 Minou Mohraz said on Wednesday that the coronavirus vaccine, COV-Iran Barekat, which has been developed by Iranian scientists at the Headquarters for Executing the Order of Imam Khomeini (HEIKO), is more efficient than the China-made Sinopharm vaccine.
“COV-Iran Barekat vaccine is more efficient than the Chinese Sinopharm,” said Mohraz, also a senior member of the team to assess the efficiency of the Iran-made vaccine.
“Based on available assessments, effectiveness of this vaccine in terms of neutralizing antibodies is about 80%; in addition, this vaccine has not shown any serious side effect,” she added.
Mohraz said a limited number of COV-Iran Barekat vaccine doses has already been supplied to the market "and by the end of June, another 2 to 3 million doses will be delivered for public vaccination, and then in the next one to two months, several million doses of the vaccine will be produced each month in the main plant".
She had also on Monday said that COV-Iran Barekat vaccine is efficient and has no significant side effects.
“Barekat vaccine has no side effects and one million doses of the vaccine are ready (for injection),” said Mohraz.
She also assured people not to be worried about the shortage of foreign vaccines in Iran, saying that even those who have received the first dose of imported vaccines can use COV-Iran vaccine for their second dose.
In relevant remarks late last month, Head of HEIKO Mohammad Mokhber said that nearly 30 million doses of COV-Iran Barekat vaccine will be produced and delivered to the health ministry.
“One million doses of the vaccine will be produced this month, 3 million doses next month, 10 to 12 million doses in July, and 13 to 15 million doses in August,” Mokhber said, adding that the vaccines would be given to the Health Ministry for vaccination.
He noted that from September, 20 million doses of the vaccine would be produced monthly.
The official pointed out that people's concerns regarding the virus would be resolved within the next 3 to 4 months.
He concluded that all Iranian vaccines had achieved the human testing phase and desirable results, but COV-Iran Barekat has had fewer side effects.